Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 2/2016

SMALL LDL: A HELPFUL PARTICLE IN MONITORING PATIENTS WITH METABOLIC SYNDROME

DANIELA CRISTINA DIMITRIU1#, CORNELIA MIRCEA2#*, CĂTĂLIN PRICOP1,3#, OVIDIU MITU1,4#, RALUCA STĂNESCU1#, MONICA HĂNCIANU2#, ELENA PETRESCU-DĂNILĂ1#

1.“Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Medicine, 16 Universităţii Street, 700115, Iași, Romania
2 .“Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Pharmacy, 16 Universităţii Street, 700115, Iași, Romania
3 .“C. I. Parhon” Hospital, 50 Carol I Boulevard, 700503, Iași, Romania
4 .“Sf. Spiridon” Clinical Emergency Hospital, 1 Independenţei Boulevard, 700111, Iași, Romania

Download Full Article PDF

Patients with metabolic syndrome have a higher risk of cardiovascular events than healthy subjects. Many studies proved that plasma lipoprotein levels represent predictive factors for coronary disease. Among lipoproteins, small low density lipoproteins (sLDL) particles have the highest atherogenic potential. For patients with metabolic syndrome, levels of plasma sLDL, as compared to other lipid markers that constitute cardiovascular risk factors, and correlated with carotid artery intima-media thickness (IMT) measured by ultrasound imaging, may represent useful markers for medical and pharmaceutical practice.